Payment overview · 2025
General Payments
$233.44
13 reported records · 8 companies
Healthcare provider profile · identity verified
John J Ingram, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALCOA, TN · NPI 1053480996
Verified facts
What the public records show
CMS Open Payments records show John J Ingram, MD received $233.44 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.64 | 24.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.25 | 21.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.99 | 14.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.55 | 12.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.22 | 8.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.51 | 6.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.77 | 5.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.51 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.44 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.64 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.64 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.25 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $33.99 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 137 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 360 | 96 |
| Losartan Potassium | Losartan Potassium | 304 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 265 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 61 |
| Omeprazole | Omeprazole | 224 | 59 |
| Simvastatin | Simvastatin | 214 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 52 |
| Alprazolam | Alprazolam | 174 | 29 |
| Gabapentin | Gabapentin | 166 | 33 |
| Potassium Chloride | Potassium Chloride | 164 | 47 |
| Furosemide | Furosemide | 140 | 43 |
| Eliquis | Apixaban | 137 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 35 |
| Prednisone | Prednisone | 134 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 34 |
| Metformin Hcl Er | Metformin Hcl | 85 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 81 | 21 |
| Allopurinol | Allopurinol | 77 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 19 |
| Trazodone Hcl | Trazodone Hcl | 68 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 11 |
| Metformin Hcl | Metformin Hcl | 65 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 18 |
| Ezetimibe | Ezetimibe | 62 | 17 |
| Benazepril Hcl | Benazepril Hcl | 60 | 15 |
| Meloxicam | Meloxicam | 60 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 17 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 15 |
| Warfarin Sodium | Warfarin Sodium | 51 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 13 |
| Lisinopril | Lisinopril | 45 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Tramadol Hcl | Tramadol Hcl | 41 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 38 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 25 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | 11 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 24 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Nitro-Bid | Nitroglycerin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $233.44 · 13 records | Novo Nordisk Inc | AIRSUPRA, CAPVAXIVE, ELIQUIS, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, VAXNEUVANCE, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error